Want to see CAPR full AI Analyst Report?
CAPR Stock Chart & Stats
$34.70
-$0.36(-2.53%)
At close: 4:00 PM EST
$34.70
-$0.36(-2.53%)
Day’s Range― - ―
52-Week Range$4.30 - $40.37
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.09M
Market Cap
$1.64B
Enterprise Value$1.19B
Total Cash (Recent Filing)$278.61M
Total Debt (Recent Filing)$21.12M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Aug 12, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding57,911,892
10 Day Avg. Volume1,186,665
30 Day Avg. Volume1,087,791
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-18.45
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-27.99
Enterprise Value/Ebitda1.33
Forecast
1Y Price Target
$53.00Price Target Upside52.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$131.21M
Bulls Say, Bears Say
Bulls Say
Pivotal Phase 3 Efficacy (HOPE‑3)Statistically significant Phase 3 results provide durable proof-of-concept for deramiocel in DMD, underpinning a credible approval case, stronger label claims, and clinical adoption. Robust cardiac secondary outcomes broaden clinical value and raise entry barriers versus smaller competing programs.
Active BLA Review With Clear PDUFA TimelineAn accepted Class 2 BLA and explicit PDUFA date materially reduce regulatory timing uncertainty, enabling management to finalize commercial planning, manufacturing validation sequencing, and potential PRV monetization. This structural clarity supports execution and capital-allocation decisions over the next 2–6 months.
In‑house GMP Manufacturing & Staged Scale PlanOwning an FDA‑inspected GMP facility and a defined expansion path gives Capricor control over supply, reduces third-party dependency, and enables phased commercial scale-up. Internal manufacturing supports launch readiness, potential margin capture, and faster response to demand if regulatory approval is secured.
Bears Say
Litigation Over U.S. Distribution RightsOngoing litigation to unwind the NS Pharma agreement creates structural uncertainty around U.S. commercialization, could delay go‑to‑market timing, and risks management distraction. Potential court outcomes and injunctions may alter distribution plans and impose legal costs or contractual repayments.
Zero Recent Revenue And Persistent Cash BurnThe company reports no current product revenue and materially negative operating and free cash flows, indicating weak internal cash generation. Even with ~$279M on hand, continued elevated burn and rising OpEx mean sustainability hinges on approval commercialization or external financing within the next 12–18 months.
Payer/pricing And Access ComplexityStructural reimbursement risk from transfer‑pricing and ASP/AMP dynamics could materially constrain patient access and net pricing post‑approval. Even with regulatory clearance, unfavorable payer mechanics or unresolved pricing design could limit uptake and revenue realization over the medium term.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics, Inc.’s price range in the past 12 months?
Capricor Therapeutics, Inc. lowest stock price was $4.30 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics, Inc.’s market cap?
Capricor Therapeutics, Inc.’s market cap is $1.64B.
When is Capricor Therapeutics, Inc.’s upcoming earnings report date?
Capricor Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 37 days.
How were Capricor Therapeutics, Inc.’s earnings last quarter?
Capricor Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.507 by -$0.083.
Is Capricor Therapeutics, Inc. overvalued?
According to Wall Street analysts Capricor Therapeutics, Inc.’s price is currently Undervalued.
Does Capricor Therapeutics, Inc. pay dividends?
Capricor Therapeutics, Inc. does not currently pay dividends.
What is Capricor Therapeutics, Inc.’s EPS estimate?
Capricor Therapeutics, Inc.’s EPS estimate is -0.59.
How many shares outstanding does Capricor Therapeutics, Inc. have?
Capricor Therapeutics, Inc. has 57,911,892 shares outstanding.
What happened to Capricor Therapeutics, Inc.’s price movement after its last earnings report?
Capricor Therapeutics, Inc. reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.507. Following the earnings report the stock price went down -3.775%.
Which hedge fund is a major shareholder of Capricor Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.00 (52.74% Upside)
$53.00 (52.74% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 149.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
131.63%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
112.19%
Trailing 12-Months
Company Description
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
CAPR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory progress for deramiocel — statistically significant phase 3 efficacy (primary and cardiac secondary endpoints), robust long-term safety exposure, active BLA review with a clear PDUFA date, in-house manufacturing capabilities and a solid cash runway. Management also articulated a concrete commercialization plan and eligibility for a monetizable Priority Review Voucher. Offsetting these positives are notable near-term risks: an active lawsuit with NS Pharma that creates distribution uncertainty (and potential need to repay $50M), rising operating expenses and no current product revenue, manufacturing labeling constraints for an ultra-cold-chain therapy, and unresolved ASP/AMP payer complexities that could affect access. On balance, the material clinical/regulatory achievements and internal control of manufacturing and cash resources outweigh the legal and commercial execution risks, but the litigation and payer/pricing issues remain important near-term uncertainties.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$53.00
▲(52.74% Upside)
Technical Analysis
Ownership Overview
0.93% Insiders
8.19% Mutual Funds
27.28% Other Institutional Investors
51.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---